Humacyte, Inc. Common Stock (HUMA) Stock Price
HUMAStock
$0.43−74.76%52W
Market Cap$119.18M
P/E—
PEG Ratio—
Div yield—
Beta2.77
HUMA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-47.82%
Price vs S&P 500 (4W)-25.96%
VGM Score40.53
HUMA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.10 | -$0.16 | -54.84%(-$0.06) | |
| Q1 2026 | -$0.12 | -$0.09 | +21.74%(+$0.03) | |
| Q4 2025 | -$0.14 | -$0.13 | +3.70%(+$0.01) | |
| Q3 2025 | -$0.15 | -$0.11 | +25.80%(+$0.04) | |
| Q2 2025 | -$0.18 | -$0.24 | -35.85%(-$0.06) |
HUMA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.09
4.09
4.09
4.09
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
HUMAHumacyte, Inc. Common Stock | D | C | D | 56.2x | 231.7% | -494.6% | — | $0.43 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Humacyte, Inc. Common Stock
Humacyte develops acellular bioengineered human tissues for therapeutic applications in vascular disease, peripheral arterial disease, dialysis access, and organ reconstruction. The company's tissue engineering platform aims to create universally implantable solutions that reduce rejection risk and address significant unmet medical needs across multiple therapeutic areas.